Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Biogen Inc.    BIIB

BIOGEN INC.

(BIIB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

FDA Accepts Biogen, Samsung Bioepis Filing for Lucentis Biosimilar

11/18/2020 | 07:37am EST

By Colin Kellaher

Samsung Bioepis Co. and Biogen Inc. on Wednesday said the U.S. Food and Drug Administration accepted for review their biologics license application for SB11, a proposed biosimilar to Roche Holdings AG's blockbuster eye drug Lucentis.

Biosimilars are near-copies of biologic drugs that are made from living cells and are analogous to generic copies of traditional pill-form medicines.

Roche's Lucentis is a therapy for retinal vascular disorders, which are a leading cause of blindness in the U.S.

SB11, if approved, would join a growing number of biosimilars developed by Samsung Bioepis, a joint venture between Biogen and Samsung BioLogics Co., and commercialized by Biogen.

Last November, Biogen and Samsung Bioepis said they would pursue ophthalmology biosimilar candidates for Lucentis and Regeneron Pharmaceuticals Inc.'s Eylea.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

11-18-20 0736ET

Stocks mentioned in the article
ChangeLast1st jan.
BIOGEN INC. -0.60% 278.44 Delayed Quote.14.47%
REGENERON PHARMACEUTICALS -0.31% 515.69 Delayed Quote.7.20%
SAMSUNG BIOLOGICS CO.,LTD. -1.47% 804000 End-of-day quote.-2.66%
SAMSUNG ELECTRONICS CO., LTD. -1.90% 88000 End-of-day quote.8.64%
All news about BIOGEN INC.
01/14BIOGEN : Aducanumab data review and Q&A with Alzheimer's Disease International
PU
01/13BIOGEN : to Report Fourth Quarter and Full Year 2020 Financial Results February ..
PU
01/13DENALI THERAPEUTICS : Strategic Outlook, Upcoming Data for DNL310 Warrant Price ..
MT
01/13BIOGEN : A statement about Biogen Political Action Committee
PU
01/12DEADLINE TODAY : The Schall Law Firm Announces the Filing of a Class Action Laws..
PR
01/11EISAI : Lilly Alzheimer's drug slows mental, functional decline in mid-stage tri..
RE
01/11ELI LILLY AND : Lilly Alzheimer's Drug Helped Patients in Small Trial -- Update
DJ
01/11BIOGEN : Announces First Patient Treated in RESPOND Study Evaluating Benefit of ..
AQ
01/11BIOGEN : to Participate in Webinar with Alzheimer's disease International on Jan..
AQ
01/11BIOGEN : to Launch Study to Develop Digital Biomarkers of Cognitive Health Using..
MT
More news
Financials (USD)
Sales 2020 13 389 M - -
Net income 2020 4 274 M - -
Net Debt 2020 2 827 M - -
P/E ratio 2020 10,5x
Yield 2020 -
Capitalization 43 131 M 43 131 M -
EV / Sales 2020 3,43x
EV / Sales 2021 3,82x
Nbr of Employees 7 400
Free-Float 86,1%
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | BIIB | US09062X1037 | MarketScreener
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 33
Average target price 292,50 $
Last Close Price 280,29 $
Spread / Highest target 60,5%
Spread / Average Target 4,36%
Spread / Lowest Target -37,6%
EPS Revisions
Managers and Directors
NameTitle
Michel Vounatsos Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Alfred W. Sandrock Chief Medical Officer & EVP-Research & Development
Mark Hernon Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN INC.14.47%43 131
CSL LIMITED-4.30%95 982
SAMSUNG BIOLOGICS CO.,LTD.-1.21%49 217
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.-5.54%34 529
ALEXION PHARMACEUTICALS, INC.0.13%34 282
CELLTRION HEALTHCARE CO LTD--.--%21 767